Results 161 to 170 of about 1,662 (181)
Some of the next articles are maybe not open access.
Cornea, 2013
To report 7 cases of recurrent corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab for the treatment of corneal NV-induced lipid keratopathy.We conducted a prospective interventional case series that included 20 eyes of chronic lipid keratopathy that received bevacizumab injection for the treatment of ...
Hsiao-Sang, Chu +3 more
openaire +2 more sources
To report 7 cases of recurrent corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab for the treatment of corneal NV-induced lipid keratopathy.We conducted a prospective interventional case series that included 20 eyes of chronic lipid keratopathy that received bevacizumab injection for the treatment of ...
Hsiao-Sang, Chu +3 more
openaire +2 more sources
International Ophthalmology, 2014
The purpose of this study is to investigate whether subconjunctival and/or intrastromal Bevacizumab injections could help to prevent graft failure in high-risk keratoplasties. Twenty seven eyes of 27 patients, affected by high immune rejection risk and corneal neovascularization, were involved in this prospective interventional case-control series ...
Romina, Fasciani +4 more
openaire +2 more sources
The purpose of this study is to investigate whether subconjunctival and/or intrastromal Bevacizumab injections could help to prevent graft failure in high-risk keratoplasties. Twenty seven eyes of 27 patients, affected by high immune rejection risk and corneal neovascularization, were involved in this prospective interventional case-control series ...
Romina, Fasciani +4 more
openaire +2 more sources
Cornea, 2011
Recent studies support the use of bevacizumab to treat ocular neovascularization (NV). In this study, we aimed to investigate changes in growth factors and cytokines in human tears after a subconjunctival bevacizumab injection and to evaluate the clinical effects and safety of the drug in ocular surface NV.Bevacizumab (5 mg/0.2 mL) was injected into ...
Jae Hoon, Jeong +3 more
openaire +2 more sources
Recent studies support the use of bevacizumab to treat ocular neovascularization (NV). In this study, we aimed to investigate changes in growth factors and cytokines in human tears after a subconjunctival bevacizumab injection and to evaluate the clinical effects and safety of the drug in ocular surface NV.Bevacizumab (5 mg/0.2 mL) was injected into ...
Jae Hoon, Jeong +3 more
openaire +2 more sources
Evaluation of Adjunctive Subconjunctival Injection of Bevacizumab before Pterygium Surgery
The Egyptian Journal of Hospital MedicineBackground: Pterygium is a common ocular surface lesion involves the bulbar conjunctiva's fibrovascular expansion onto the cornea. The exact cause of pterygium remains unclear, however exposure to ultraviolet radiation is recognized as a significant contributing element.
Mohamed, Mahmoud Abdelbadie +2 more
openaire +3 more sources
Journal of American Association for Pediatric Ophthalmology and Strabismus, 2012
Bevacizumab is widely used for several ocular conditions, including age-related macular degeneration, diabetic retinopathy, corneal neovascularization, neovascular glaucoma, and retinopathy of prematurity. We describe a 14-year-old patient with Stevens-Johnson syndrome in whom subconjunctival injection of bevacizumab in one eye caused bilateral ...
Siddharth, Kesarwani +2 more
openaire +2 more sources
Bevacizumab is widely used for several ocular conditions, including age-related macular degeneration, diabetic retinopathy, corneal neovascularization, neovascular glaucoma, and retinopathy of prematurity. We describe a 14-year-old patient with Stevens-Johnson syndrome in whom subconjunctival injection of bevacizumab in one eye caused bilateral ...
Siddharth, Kesarwani +2 more
openaire +2 more sources
Journal of Clinical & Experimental Ophthalmology, 2011
Corneal neovascularization caused by various ocular conditions such as infectious, inflammatory, degenerative, or traumatic diseases of the cornea and the injury of the limbal stem cell barrier. It is often accompanied by corneal scarring, stromal edema, lipid deposition, and inflammation and is associated with significant visual impairment and poor ...
openaire +1 more source
Corneal neovascularization caused by various ocular conditions such as infectious, inflammatory, degenerative, or traumatic diseases of the cornea and the injury of the limbal stem cell barrier. It is often accompanied by corneal scarring, stromal edema, lipid deposition, and inflammation and is associated with significant visual impairment and poor ...
openaire +1 more source
Journal francais d'ophtalmologie, 2016
To evaluate and compare the efficacy of subconjunctival bevacizumab injections alone, photodynamic therapy alone and combined treatments for reduction of corneal neovascularization.This study was conducted as a prospective case series. A total of seven eyes of 7 patients with corneal neovascularization caused by ocular surface disorders including ...
J, Hamdan +4 more
openaire +1 more source
To evaluate and compare the efficacy of subconjunctival bevacizumab injections alone, photodynamic therapy alone and combined treatments for reduction of corneal neovascularization.This study was conducted as a prospective case series. A total of seven eyes of 7 patients with corneal neovascularization caused by ocular surface disorders including ...
J, Hamdan +4 more
openaire +1 more source
Subconjunctival injection of bevacizumab for recurrent conjunctival papilloma: a case report
Canadian Journal of Ophthalmology, 2017Chia-Yi, Lee +4 more
openaire +2 more sources